進階篩選

Technical category
  • 共有:2筆資料
  • 顯示:
  • 筆商品
    • 定量新冠病毒中和抗體創新技術

      FutureTech 定量新冠病毒中和抗體創新技術

      A virus NT was performed in a biosafety level 3 laboratory to determine the titers. A SARS-CoV-2 enzyme-linked immunosorbent assay (ELISA) was designed to detect neutralizing antibodies in the serum, based on the binding affinity of SARS-CoV-2 viral protein 1viral protein 2 to antibodies. ELISA results viral protein 12, generated comparable neutralizing antibody titers. The results analyzed by spline regressiontwo-variable generalized additive model precisely reflected the real NT value. Our method can serve as a surrogate to quantify neutralizing antibody titer.
    • 開發鈀奈米薄膜電化學感測平台用於病毒檢測與抑制分子篩選

      Precision Health Ecosystem FutureTech 開發鈀奈米薄膜電化學感測平台用於病毒檢測與抑制分子篩選

      Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected human cell through ACE2. This study is developing a Pd nano-thin film electrode for electrochemical impedance spectroscopy. This invention can quantify neutralize antibody too. The detection platform can be used to screen 1 microliter anti-virus infection drug sample within 21 mins. Compare to SPR standard, our invention only needs 1/10000 concentration of ACE2reaction volume is ~1/30 than SPR. This invention can be adapted in detection of cancer markers,other emergency infection diseasestherapeutic drugs, too.
  • 1